Onyx down on Phase II RCC data

ONXX was off $13.47 (33%) to $27.34 on 17.8 million shares on Monday after it and partner Bayer (FSE:BAYG; BAY) reported mixed results from a placebo-controlled Phase II trial

Read the full 294 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE